Browse evidence-based analysis of health-related claims and assertions
Adding GA3 hormone helped soybean stems grow longer in the dark but didn't help them grow under blue light, showing blue light's effect couldn't be undone by this hormone.
In tall soybeans, the balance between growth hormone GA3 and stress hormone JA strongly predicted plant height, while in short soybeans, GA3 and strigolactones were the key ratio for height.
Under blue light, the stress hormone salicylic acid increased by about 56% in tall soybeans and 41% in short soybeans compared to plants grown in the dark.
Blue light made the levels of a key growth hormone (GA3) drop by about 14% in tall soybeans and 20% in short soybeans when grown in the dark versus under blue light.
When soybean plants were exposed to blue light, their height dropped by about two-thirds compared to plants grown in the dark, with both tall and short varieties showing similar reductions.
Using belly fat and good cholesterol levels before surgery predicts belly fat loss better than just measuring weight or waist size alone.
The scoring tool's predictions matched real-world results very well in both the original and new patient groups, meaning it's reliable for clinical use.
A person's waist-to-hip ratio was initially linked to belly fat loss after surgery, but this connection disappeared when considering other factors like belly fat and cholesterol levels before surgery.
People with high blood pressure initially seemed to lose more belly fat after surgery, but this link disappeared when considering other factors like belly fat and cholesterol levels before surgery.
Women were initially thought to lose more belly fat after surgery, but this difference disappeared when considering other factors like cholesterol and belly fat levels before surgery.
A simple scoring tool using belly fat and good cholesterol levels before surgery can accurately predict how much belly fat will be lost after surgery, with 88% accuracy in new patient groups.
People with higher levels of 'good' cholesterol before surgery tend to lose more belly fat after the surgery, with each unit increase in good cholesterol linked to over 10 times higher chance of bigger fat loss.
People with more belly fat before surgery tend to lose more belly fat after the surgery, with each extra square centimeter of belly fat before surgery linked to a slightly higher chance of bigger fat loss.
Even after accounting for belly fat loss, tesamorelin still increased paraspinal muscle density by 1.58 units in people with HIV and belly fat, showing a direct muscle effect.
Tesamorelin increased rectus lean muscle by 0.85 cm² in people with HIV and belly fat, and this effect stayed strong even after considering belly fat loss.
Changes in a growth hormone-related factor didn't match changes in muscle density or size in people with HIV and belly fat taking tesamorelin.
Tesamorelin increased rectus and psoas muscle size by 0.44 and 0.46 cm² in people with HIV and belly fat, and this effect remained even after accounting for belly fat loss.
Even after accounting for belly fat loss, tesamorelin still increased lean muscle in people with HIV and belly fat, suggesting other factors are involved.
Tesamorelin increased rectus muscle density by 3.5 units in people with HIV and belly fat, which is about the same difference seen between people with and without back pain in other research.
Tesamorelin increased rectus and psoas muscle size by 0.44 and 0.46 cm² in people with HIV and belly fat, but this effect was reduced when considering changes in a growth hormone-related factor.
In people with HIV and belly fat who responded to tesamorelin, muscle density changes were linked to belly fat loss but not to changes in a growth-related hormone.
People with HIV and belly fat who responded to tesamorelin had 0.64 to 1.08 square centimeters more lean muscle in their trunk muscles compared to those who didn't take the drug.
For people with HIV and belly fat who responded to tesamorelin, the drug helped increase muscle density in their trunk muscles by 1.56 to 4.86 units compared to those who didn't take it.
For Japanese adults with type 2 diabetes on sitagliptin, ipragliflozin reduces waist size more than metformin after 24 weeks, with a noticeable difference in how much waist circumference decreases.